Cercare

La salute è un diritto umano fondamentale e il conseguimento della parità di accesso ai medicinali è essenziale per garantire la salute pubblica. L'attuale sistema di innovazione farmaceutica dipende in larga misura dal settore privato e la remunerazione dell'innovazione si fonda principalmente sulle esclusive. Tale sistema comporta svariate sfide, come ad esempio il fatto che l'innovazione è guidata dalla dimensione del mercato, il parziale disallineamento fra le priorità di ricerca e sviluppo dell'industria ...

Il presente studio fornisce una mappatura dei finanziamenti forniti da diversi attori per la ricerca e lo sviluppo (R&S) e l'ampliamento della capacità di produzione dei vaccini contro la COVID-19, con particolare rifermento a quelli autorizzati nell'UE. Vengono esaminati nove vaccini. È emerso che i governi, principalmente gli Stati Uniti (insieme ad alcuni organismi senza scopo di lucro) hanno sostenuto in modo decisivo gli investimenti delle imprese, sia per quanto riguarda le attività di R&S ...

Antimicrobial resistance (AMR) is a global, multidimensional phenomenon occurring in humans, animals, and environmental ecosystems. It is the ability of microbes, e.g. bacteria, viruses, fungi and protozoa, to survive in the presence of medicines designed to kill or inactivate them (antimicrobials: antibiotics, antivirals, antifungals and antiprotozoals). At patient level, AMR hampers the effective treatment of microbial infections, leading to prolonged, severe disease and, in some cases, death. ...

Cancer can affect everyone, regardless of age, gender or social status and puts immense pressure on European health systems. Fighting cancer is one of the priorities of the European Health Union. Delivering better long-term care for patients living with cancer also means reducing significant disparities, both between and within Member States. World Cancer Day, marked every year on 4 February, reminds us that cancer is a huge health threat to our society.

The European Commission plans to launch its revised EU pharmaceutical package in the first quarter of 2023. Ahead of its release, two recent STOA studies offer insight to inform upcoming Parliamentary discussions. Fragmentation of EU health research and development, lack of transparency and a translation gap between public investment and clinical output are among the weaknesses identified. Possible solutions include the creation of large-scale European biomedical infrastructure, and a series of targeted ...

World AIDS Day, proclaimed by the United Nations in 1988, takes place each year on 1 December. The aim is to raise awareness, fight prejudice, encourage progress in prevention, and improve treatment around the world. Although infection with the human immunodeficiency virus (HIV) is preventable, significant HIV transmission remains a challenge to EU Member States' health systems. This year's theme 'Equalize' underlines the urgent need to address the inequalities that are holding back progress in ending ...

These proceedings summarise the presentations and discussions before the European Parliament’s Health Working Group as part of the workshop on ‘New incentives to improve the accessibility and availability of antimicrobial medicinal products’, held on 26 October 2022. The five presentations touched, inter alia, upon the burden of AMR, the current research on development of antimicrobials, and incentive models. These workshop proceedings were provided by the Policy Department for Economic, Scientific ...

Antimicrobial-resistant infections are predicted to become the second biggest cause of death worldwide by 2050. Despite increasing investment in the development of new antimicrobials, awareness campaigns on antimicrobial misuse and abuse, and monitoring of antimicrobial use and resistance in animals, humans and the environment, antimicrobial resistance continues to grow and the last three decades have not seen even one novel antimicrobial class reach the market. Could the answer lie in a 'Trojan ...

Durante la tornata di febbraio il Parlamento discuterà la relazione finale della sua commissione speciale sulla lotta contro il cancro e voterà una serie di raccomandazioni relative all'adozione di misure politiche specifiche in tale settore fondamentale della sanità pubblica.

As part of building a European Health Union, as well as in response to the Covid 19 pandemic, the European Commission proposed in November 2020 to reinforce the European Medicines Agency's role in crisis preparedness and the management of medicines and medical devices. The proposed regulation seeks to better anticipate possible shortages and to ensure timely development of high-quality medicinal solutions, to allow the EU to react to health crises more quickly, efficiently, and in a coordinated manner ...